Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05761301 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
A Phase 1 study, sponsored by Alnylam Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT05761301 is a Phase 1 study that was terminated before completion, run by Alnylam Pharmaceuticals. The registered enrollment target is 49 participants.
The verdict
NCT05761301, a Phase 1 study, was terminated before completion, sponsored by Alnylam Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
Interventions
- DRUG Placebo
- DRUG ALN-KHK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05761301
The ClinicalTrials.gov registry entry for NCT05761301 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05761301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05761301 about?
NCT05761301 is a clinical study titled "A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM". To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
What is the current status of trial NCT05761301?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2023-03-10. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT05761301?
The interventions under investigation include: Placebo (DRUG), ALN-KHK (DRUG).
Who is sponsoring clinical trial NCT05761301?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.